Cargando…
Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041240/ https://www.ncbi.nlm.nih.gov/pubmed/33846824 http://dx.doi.org/10.1007/s00134-021-06395-1 |
| _version_ | 1783677901709770752 |
|---|---|
| author | Sakr, Yasser Bensasi, Hatim Taha, Ahmed Bauer, Michael Ismail, Khaled |
| author_facet | Sakr, Yasser Bensasi, Hatim Taha, Ahmed Bauer, Michael Ismail, Khaled |
| author_sort | Sakr, Yasser |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8041240 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80412402021-04-13 Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia Sakr, Yasser Bensasi, Hatim Taha, Ahmed Bauer, Michael Ismail, Khaled Intensive Care Med Letter Springer Berlin Heidelberg 2021-04-12 2021 /pmc/articles/PMC8041240/ /pubmed/33846824 http://dx.doi.org/10.1007/s00134-021-06395-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Letter Sakr, Yasser Bensasi, Hatim Taha, Ahmed Bauer, Michael Ismail, Khaled Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia |
| title | Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia |
| title_full | Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia |
| title_fullStr | Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia |
| title_full_unstemmed | Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia |
| title_short | Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia |
| title_sort | camostat mesylate therapy in critically ill patients with covid-19 pneumonia |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041240/ https://www.ncbi.nlm.nih.gov/pubmed/33846824 http://dx.doi.org/10.1007/s00134-021-06395-1 |
| work_keys_str_mv | AT sakryasser camostatmesylatetherapyincriticallyillpatientswithcovid19pneumonia AT bensasihatim camostatmesylatetherapyincriticallyillpatientswithcovid19pneumonia AT tahaahmed camostatmesylatetherapyincriticallyillpatientswithcovid19pneumonia AT bauermichael camostatmesylatetherapyincriticallyillpatientswithcovid19pneumonia AT ismailkhaled camostatmesylatetherapyincriticallyillpatientswithcovid19pneumonia AT camostatmesylatetherapyincriticallyillpatientswithcovid19pneumonia |